These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 26731686

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks.
    Martel C, Labrie F, Archer DF, Ke Y, Gonthier R, Simard JN, Lavoie L, Vaillancourt M, Montesino M, Balser J, Moyneur É, other participating members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2016 May; 159():142-53. PubMed ID: 26972555
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
    Montesino M, Labrie F, Archer DF, Zerhouni J, Côté I, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Moyneur E, Balser J.
    Gynecol Endocrinol; 2016 May; 32(3):240-5. PubMed ID: 26634942
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.
    Bachmann GA, Komi JO, Ospemifene Study Group.
    Menopause; 2010 May; 17(3):480-6. PubMed ID: 20032798
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Effects of preoperative intravaginal estrogen on pelvic floor disorder symptoms in postmenopausal women with pelvic organ prolapse.
    Rahn DD, Richter HE, Sung VW, Hynan LS, Pruszynski JE.
    Am J Obstet Gynecol; 2023 Sep; 229(3):309.e1-309.e10. PubMed ID: 37244454
    [Abstract] [Full Text] [Related]

  • 30. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J.
    Menopause; 2009 Sep; 16(5):923-31. PubMed ID: 19424093
    [Abstract] [Full Text] [Related]

  • 31. A randomized, double-blind, placebo-controlled phase 2 pilot trial evaluating a novel, vaginal softgel capsule containing solubilized estradiol.
    Pickar JH, Amadio JM, Hill JM, Bernick BA, Mirkin S.
    Menopause; 2016 May; 23(5):506-10. PubMed ID: 26836245
    [Abstract] [Full Text] [Related]

  • 32. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH.
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [Abstract] [Full Text] [Related]

  • 33. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom.
    Kroll R, Archer DF, Lin Y, Sniukiene V, Liu JH.
    Menopause; 2018 Feb; 25(2):133-138. PubMed ID: 28926514
    [Abstract] [Full Text] [Related]

  • 34. TX-004HR Improves Sexual Function as Measured by the Female Sexual Function Index in Postmenopausal Women With Vulvar and Vaginal Atrophy: The REJOICE Trial.
    Kingsberg SA, Derogatis L, Simon JA, Constantine GD, Graham S, Bernick B, Gasper G, Mirkin S.
    J Sex Med; 2016 Dec; 13(12):1930-1937. PubMed ID: 27692842
    [Abstract] [Full Text] [Related]

  • 35. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
    Portman DJ, Bachmann GA, Simon JA, Ospemifene Study Group.
    Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
    [Abstract] [Full Text] [Related]

  • 36. Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial.
    Bumphenkiatikul T, Panyakhamlerd K, Chatsuwan T, Ariyasriwatana C, Suwan A, Taweepolcharoen C, Taechakraichana N.
    BMC Womens Health; 2020 Aug 12; 20(1):173. PubMed ID: 32787848
    [Abstract] [Full Text] [Related]

  • 37. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal Symptoms Associated With Aromatase Inhibitors.
    Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ.
    J Clin Endocrinol Metab; 2018 Nov 01; 103(11):4146-4154. PubMed ID: 30239842
    [Abstract] [Full Text] [Related]

  • 38. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration.
    Ke Y, Labrie F, Gonthier R, Simard JN, Bergeron D, Martel C, Vaillancourt M, Montesino M, Lavoie L, Archer DF, Balser J, Moyneur E, other participating Members of the Prasterone Clinical Research Group.
    J Steroid Biochem Mol Biol; 2015 Nov 01; 154():186-96. PubMed ID: 26291918
    [Abstract] [Full Text] [Related]

  • 39. Early onset of action with a 17β-estradiol, softgel, vaginal insert for treating vulvar and vaginal atrophy and moderate to severe dyspareunia.
    Constantine G, Millheiser LS, Kaunitz AM, Parish SJ, Graham S, Bernick B, Mirkin S.
    Menopause; 2019 Nov 01; 26(11):1259-1264. PubMed ID: 31688572
    [Abstract] [Full Text] [Related]

  • 40. High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy.
    Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Martel C, Balser J.
    Gynecol Endocrinol; 2010 Jul 01; 26(7):524-32. PubMed ID: 20459349
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.